TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11257560
Drug: RAD co-administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD co-administration with CsA
Study: 23719547
Drug: Calcium (600
Normalized name: calcium carbonate/vitamin D3 250 mg calcium (600 mg)-125 unit ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (600 mg) plus Vitamin D3 (200 IU) supplementation
Study: 8458113
Drug: fosinopril 10
Normalized name: fosinopril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosinopril 10 mg
Study: 8458113
Drug: fosinopril 20
Normalized name: fosinopril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosinopril 20 mg
Study: 8458113
Drug: fosinopril 40
Normalized name: fosinopril 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosinopril 40 mg
Study: 24402825
Drug: Micronized curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized curcumin (500 mg)
Study: 24402825
Drug: Liquid micellar
Normalized name: Douxo Micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid micellar curcumin (500 mg)
Study: 24402825
Drug: Native curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native curcumin (500 mg)
Study: 18554243
Drug: Interferon-alpha tailored
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha tailored treatment (5 million units thrice weekly for a median of 10 months, range 6-24 months)
Study: 18554243
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Interferon-alpha 5 million units thrice weekly for 6 months)
Study: 11487307
Drug: Pranlukast hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast hydrate (225.5 mg), twice a day for 1 week
Study: 7810780
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (Group I)
Study: 2902813
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (0.01 mg/kg) after lormetazepam (0.06 mg/kg)
Study: 2902813
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (0.01 mg/kg) after flunitrazepam (0.03 mg/kg)
Study: 2902813
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (0.01 mg/kg) after placebo
Study: 1392698
Drug: Cyclical estrogen-progestagen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical estrogen-progestagen replacement treatment
Study: 1392698
Drug: Cyclical estrogen-progestagen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical estrogen-progestagen replacement treatment plus nandrolone decanoate
Study: 1392698
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Cyclical estrogen-progestagen replacement treatment and Cyclical estrogen-progestagen replacement treatment plus nandrolone decanoate)
Study: 23509019
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl 200 μg
Study: 23509019
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl 100 μg
Study: 23509019
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl (both doses)
Study: 19648781
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ROL-containing product
Study: 19648781
Drug: Tryptophan fluorescence
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tryptophan fluorescence spectroscopy in active-agent-treated group
Study: 15461622
Drug: Bortezomib 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.0 mg/m2
Study: 20952514
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m2
Study: 15461622
Drug: Bortezomib alone
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib alone or in combination with dexamethasone
Study: 11916359
Drug: Captopril 6.25
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 6.25 mg (n = 85)
Study: 11916359
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg (n = 91)
Study: 7848395
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg every day
Study: 7848395
Drug: H2RA (ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2RA (ranitidine 150 mg twice daily or famotidine 20 mg twice daily)
Study: 2904881
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy with severe hypoglycemic episodes
Study: 30517065
Drug: 37.5% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5% hydrogen peroxide (HP) gel
Study: 29961213
Drug: 6% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydrogen peroxide (HP) gel
Study: 23179176
Drug: THC/CBD spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC/CBD spray (2 sprays: 5.4 mg THC and 5.0 mg CBD, 4 sprays: 10.8 mg THC and 10.0 mg CBD, 8 sprays: 21.6 mg THC and 20.0 mg CBD)
Study: 23179176
Drug: THC/CBD spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC/CBD spray (multiple doses: 2, 4, or 8 sprays once daily for nine consecutive days)
Study: 21526980
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 400 mg of colostrum protein taken thrice daily with bicarbonate buffer
Study: 21526980
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 400 mg colostrum protein given with buffer
Study: 21526980
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 400 mg colostrum protein given without buffer
Study: 21526980
Drug: Tablets containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing 200 mg colostrum protein given without buffer
Study: 7834164
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release dosage form of sodium monofluoro phosphate (NaMFP) at a dose of 160 mg, with a drug to polymer ratio of 1:1.1, delivered over 6 hours.
Study: 7834164
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release dosage form of sodium monofluoro phosphate (NaMFP) used as a control in a two‐period crossover study.
Study: 2968885
Drug: Bedtime ultralente
Normalized name: INSULIN,ULTRALENTE,HUMAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime ultralente administration
Study: 2968885
Drug: Morning ultralente
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning ultralente administration
Study: 31149709
Drug: l-leucine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-leucine supplementation (7.5 g·d‐1) with resistance training (3 times/week)
Study: 31149709
Drug: Placebo (l-alanine)
Normalized name: L-alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo (l-alanine) with resistance training (3 times/week)
Study: 31149709
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (l-leucine and l-alanine)
Study: 25563714
Drug: Methotrexate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (10 mg orally once a week for 3 months)
Study: 25563714
Drug: Placebo (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (treatment as usual)
Study: 22801943
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily exercise until discharge home and twice weekly as outpatient for 8 weeks
Study: 20199815
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of recombinant human erythropoietin (rhEPO, 50 U/kg)
Study: 20199815
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without IV treatment before PCI
Study: 19246447
Drug: 21‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21‐mg nicotine patch for 6 months
Study: 17105759
Drug: PCI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI and stenting with optimal medical therapy
Study: 11759140
Drug: 0.1% study
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% study drug infusion with 0.6 microgram/mL of sufentanil
Study: 24667461
Drug: GLP-1 and
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 and insulin during normoglycemic-hyperinsulinemic clamp
Study: 24667461
Drug: GLP-1 and
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 and insulin during normoglycemia
Study: 17823565
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (oxygen 8 l/min via Venturi face mask)
Study: 11915588
Drug: 17 beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol 2 mg plus norethisterone acetate 1 mg (E2 + NETA)
Study: 9895083
Drug: Diclofenac (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (IV bolus of 0.7 mg/kg followed by a constant infusion of 0.15 mg x kg(‐1) x h(‐1))
Study: 9895083
Drug: Saline (equal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (equal volume administered)
Study: 8273195
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser therapy
Study: 1830287
Drug: Nifedipine/Mefruside combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine/Mefruside combination
Study: 6661343
Drug: Timolol treatment
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol treatment for 2 weeks
Study: 6661343
Drug: Carbimazole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole treatment after timolol
Study: 29205909
Drug: HAPA-treatment (sedentary
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAPA-treatment (sedentary behavior)
Study: 28848898
Drug: Indacaterol/glycopyrrolate (IND/GLY)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrrolate (IND/GLY) 27.5/15.6 or 27.5/31.2 µg twice daily (b.i.d.)
Study: 28848898
Drug: Indacaterol (IND)
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol (IND) 75 µg once daily (o.d.)
Study: 22093775
Drug: Abarelix initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abarelix initiation therapy for 12 weeks followed by LHRH agonist (leuprolide or goserelin) for 8 weeks
Study: 22093775
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist therapy (leuprolide or goserelin)
Study: 22093775
Drug: Abarelix initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abarelix initiation therapy
Study: 22093775
Drug: Abarelix initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abarelix initiation therapy and LHRH agonist maintenance therapy
Study: 20361916
Drug: Agomelatine 25
Normalized name: Agomelatine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25 mg/d
Study: 20361916
Drug: Agomelatine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 50 mg/d
Study: 10404423
Drug: Hoasca (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hoasca (2 ml/kg body weight)
Study: 19843565
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise therapy for 6 weeks, tailored to individual performance, supervised by a physical therapist, with home exercises for 3 months
Study: 7916925
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg OKT3 (initial three doses)
Study: 7916925
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg OKT3 (initial three doses)
Study: 6778673
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (water, electrolytes, and carbohydrates by intravenous route)
Study: 26474943
Drug: Telmisartan treated
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan treated dose arms
Study: 22306586
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2a (40 kD) 180 µg/week and ribavirin 800 mg/day
Study: 22306586
Drug: threshold exposures
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: threshold exposures to both drugs
Study: 22306586
Drug: ribavirin 1000
Normalized name: ribavirin 1000 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: ribavirin 1000 or 1200 mg/day
Study: 11463136
Drug: Perospirone 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perospirone 8 to 48 mg/day
Study: 11463136
Drug: Haloperidol 2
Normalized name: haloperidol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 2 to 12 mg/day
Study: 11463136
Drug: Mosapramine 50
Normalized name: mosapramine
DrugBank: Mosapramine (DB13676)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mosapramine 50 to 300 mg/day
Study: 2596678
Drug: Interpleural bupivacaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural bupivacaine, 20 ml of a 0.5% solution with adrenaline 5 micrograms/ml
Study: 2596678
Drug: Intramuscular pethidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular pethidine, 1 mg/kg
Study: 31300528
Drug: Parent-only treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-only treatment with booster sessions (n = 44)
Study: 31300528
Drug: Parent-only treatment
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-only treatment without booster sessions (n = 43)
Study: 31300528
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST) (n = 87)
Study: 25761977
Drug: Glimepiride ≤6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride ≤6 mg/day
Study: 23647373
Drug: Tefinostat (CHR‐2845)
Normalized name: Belinostat
DrugBank: Tefinostat (DB15321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tefinostat (CHR‐2845) at doses of 20‐640 mg, administered orally once daily.
Study: 17106267
Drug: rDEN2/4Delta30(ME) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rDEN2/4Delta30(ME) vaccine at a dose of 1,000 PFU
Study: 17106267
Drug: rDEN2/4Delta30(ME) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rDEN2/4Delta30(ME) vaccine
Study: 9280873
Drug: Cisplatin in
Normalized name: cisplatin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin in combination with prolonged oral etoposide (100 mg/d for 14 days)
Study: 9280873
Drug: Prolonged oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged oral etoposide therapy (100 mg/d for 14 or 21 days)
Study: 9280873
Drug: Cisplatin in
Normalized name: cisplatin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin in combination with prolonged oral etoposide
Study: 8516090
Drug: Phototherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phototherapy plus oral agar
Study: 8516090
Drug: Oral agar
Normalized name: Agar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral agar alone
Study: 3102414
Drug: 4MV photon
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4MV photon therapy
Study: 26980264
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem (3 times a day)
Study: 24448757
Drug: Cystone supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystone supplement with cisplatin (group B)
Study: 11022177
Drug: Subcutaneous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous octreotide (mean exposure of 3 years); n=231
Study: 11022177
Drug: Intramuscular Sandostatin
Normalized name: Sandostatin
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular Sandostatin LAR (mean exposure of 2.5 years); n=47
Study: 18836324
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream (SSC)
Study: 10225478
Drug: ACE-Inhibitors
Normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-Inhibitors
Study: 10225478
Drug: no pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: no pharmacological treatment
Study: 8550304
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injections of narcotics
Study: 95728
Drug: Minoxidil in
Normalized name: Product containing minoxidil in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil in combination with propranolol and diuretics
Study: 95728
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs (comparable group)
Study: 28617838
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tesamorelin
Study: 23975476
Drug: Fluoxetine (directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (directly observed treatment)
Study: 16815689
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of piperacillin (2 g i.v. over 0.5 h as a loading dose followed by 8 g i.v. daily over 24 h)
Study: 16815689
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of piperacillin (3 g i.v. every 6h over 0.5 h)
Study: 16815689
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of piperacillin
Study: 15049402
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg tablet once daily for 2 weeks
Study: 9491825
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (FBF ratios)
Study: 9491825
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (FBF)
Study: 9491825
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion (FBF ratios)
Study: 9491825
Drug: Noradrenaline infusion
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenaline infusion (FBF)
Study: 7828793
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg b.i.d.)
Study: 3144615
Drug: Short-term MF
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term MF chemotherapy (mitomycin C 0.04 mg/kg plus 5-fluorouracil 5.0 mg/kg x 6 bolus i.v.)
Study: 3144615
Drug: MF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF plus long-term HCFU chemotherapy (HCFU 6-12 mg/kg/day over 12 weeks, p.o.)
Study: 30113526
Drug: Canagliflozin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (300 mg daily)
Study: 23385285
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m), Carboplatin (6 times AUC), Vorinostat (200 mg) every 28 days for 6 cycles
Study: 23385285
Drug: Paclitaxel (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (135 mg/m) and Vorinostat (400 mg) maintenance chemotherapy every 28 days for 12 cycles
Study: 23385285
Drug: Primary induction
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary induction chemotherapy
Study: 20951505
Drug: TARGeted Intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARGeted Intraoperative radioTherapy (Targit) boost with a single dose of 20 Gy
Study: 17236593
Drug: rhGH 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH 0.15 U/kg daily from day 3 to day 9 after operation
Study: 12895016
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy based on a two‐stage model of trauma treatment including Dialectical Behavior Therapy skills and writing assignments
Study: 9751910
Drug: 75 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 microg/kg each of morphine and midazolam
Study: 9751910
Drug: 75 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 microg/kg morphine and 50 microg/kg midazolam
Study: 9751910
Drug: 50 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg/kg morphine and 75 microg/kg midazolam
Study: 9751910
Drug: 50 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg/kg each of morphine and midazolam
Study: 3940501
Drug: Cimetidine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1200 mg/d) + Metoclopramide (40 mg/d)
Study: 3940501
Drug: Cimetidine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1200 mg/d) + Placebo
Study: 26984513
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise (PE) program, 0.5-1 hour duration at least twice weekly for at least 3 months, with continuation encouraged thereafter.
Study: 22951014
Drug: Celecoxib 400mg
Normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400mg b.i.d. in combination with two-drug platinum-based chemotherapy
Study: 22951014
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with two-drug platinum-based chemotherapy
Study: 19960257
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with amantadine (200 mg daily)